Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether recombinant human hepatocyte growth factor is safe and effective in the treatment of fulminant and late-onset hepatic failure.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto University, Graduate School of Medicine
• Treatments: Mitogens

Criteria

Inclusion Criteria:

• Clinical diagnosis of fulminant or late-onset hepatic failure

• Must be unable to receive liver transplantation

Exclusion Criteria:

• Under 16 years old

• Cancer patients

• Pregnancy-aged women

• Impaired renal function

• Impaired cardiac function

• Severe complications including pneumonia, sepsis, DIC and so on